P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

Detalles Bibliográficos
Autores principales: Gupta, V., Yacoub, A., Verstovsek, S., Mesa, R. A., Harrison, C. N., Barosi, G., Kiladjian, J.-J., Deeg, H. J., Fazal, S., Foltz, L., Mattison, R. J., Miller, C. B., Parameswaran, V., Hernandez, C., Zhang, J., Talpaz, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431359/
http://dx.doi.org/10.1097/01.HS9.0000847036.30498.e9
_version_ 1784780033153302528
author Gupta, V.
Yacoub, A.
Verstovsek, S.
Mesa, R. A.
Harrison, C. N.
Barosi, G.
Kiladjian, J.-J.
Deeg, H. J.
Fazal, S.
Foltz, L.
Mattison, R. J.
Miller, C. B.
Parameswaran, V.
Hernandez, C.
Zhang, J.
Talpaz, M.
author_facet Gupta, V.
Yacoub, A.
Verstovsek, S.
Mesa, R. A.
Harrison, C. N.
Barosi, G.
Kiladjian, J.-J.
Deeg, H. J.
Fazal, S.
Foltz, L.
Mattison, R. J.
Miller, C. B.
Parameswaran, V.
Hernandez, C.
Zhang, J.
Talpaz, M.
author_sort Gupta, V.
collection PubMed
description
format Online
Article
Text
id pubmed-9431359
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-94313592022-08-31 P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX) Gupta, V. Yacoub, A. Verstovsek, S. Mesa, R. A. Harrison, C. N. Barosi, G. Kiladjian, J.-J. Deeg, H. J. Fazal, S. Foltz, L. Mattison, R. J. Miller, C. B. Parameswaran, V. Hernandez, C. Zhang, J. Talpaz, M. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431359/ http://dx.doi.org/10.1097/01.HS9.0000847036.30498.e9 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Gupta, V.
Yacoub, A.
Verstovsek, S.
Mesa, R. A.
Harrison, C. N.
Barosi, G.
Kiladjian, J.-J.
Deeg, H. J.
Fazal, S.
Foltz, L.
Mattison, R. J.
Miller, C. B.
Parameswaran, V.
Hernandez, C.
Zhang, J.
Talpaz, M.
P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title_full P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title_fullStr P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title_full_unstemmed P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title_short P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)
title_sort p1042: safety and tolerability results from the phase 3b freedom trial of fedratinib (fedr), an oral, selective jak2 inhibitor, in patients with myelofibrosis (mf) previously treated with ruxolitinib (rux)
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431359/
http://dx.doi.org/10.1097/01.HS9.0000847036.30498.e9
work_keys_str_mv AT guptav p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT yacouba p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT verstovseks p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT mesara p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT harrisoncn p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT barosig p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT kiladjianjj p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT deeghj p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT fazals p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT foltzl p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT mattisonrj p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT millercb p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT parameswaranv p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT hernandezc p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT zhangj p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux
AT talpazm p1042safetyandtolerabilityresultsfromthephase3bfreedomtrialoffedratinibfedranoralselectivejak2inhibitorinpatientswithmyelofibrosismfpreviouslytreatedwithruxolitinibrux

Ejemplares similares